Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;41(4):471-482.
doi: 10.1038/s41401-020-0365-y. Epub 2020 Feb 28.

Recent advances in dopaminergic strategies for the treatment of Parkinson's disease

Qi Mao #  1 , Wang-Zhi Qin #  1 , Ao Zhang  2   3   4 , Na Ye  5
Affiliations
Review

Recent advances in dopaminergic strategies for the treatment of Parkinson's disease

Qi Mao et al. Acta Pharmacol Sin. 2020 Apr.

Abstract

Parkinson's disease (PD) is the second most common progressive neurodegenerative disease worldwide. However, there is no available therapy reversing the neurodegenerative process of PD. Based on the loss of dopamine or dopaminergic dysfunction in PD patients, most of the current therapies focus on symptomatic relief to improve patient quality of life. As dopamine replacement treatment remains the most effective symptomatic pharmacotherapy for PD, herein we provide an overview of the current pharmacotherapies, summarize the clinical development status of novel dopaminergic agents, and highlight the challenge and opportunity of emerging preclinical dopaminergic approaches aimed at managing the features and progression of PD.

Keywords: D1 receptor; D2 receptor; Parkinson’s disease; allosteric modulator; dopamine; drug discovery and development; multitarget; neurodegenerative diseases; neuroprotection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Schematic of various strategies for PD treatment
Fig. 2
Fig. 2
Dopaminergics undergoing clinical trials
Fig. 3
Fig. 3
Other dopaminergics examined in preclinical studies
Fig. 4
Fig. 4
Selective MAO-B inhibitors for preclinical PD treatment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3:17013. doi: 10.1038/nrdp.2017.13. - DOI - PubMed
    1. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009;373:2055–66. doi: 10.1016/S0140-6736(09)60492-X. - DOI - PubMed
    1. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, et al. Pathophysiology of the basal ganglia in Parkinson’s disease. Trends Neurosci. 2000;23:S8–19. doi: 10.1016/S1471-1931(00)00028-8. - DOI - PubMed
    1. Vu TC, Nutt JG, Holford NH. Progression of motor and nonmotor features of parkinson's disease and their response to treatment. Br J Clin Pharm. 2012;74:267–83. doi: 10.1111/j.1365-2125.2012.04192.x. - DOI - PMC - PubMed
    1. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889–909. doi: 10.1016/S0896-6273(03)00568-3. - DOI - PubMed